Evidence map›Paper›PMID 36298469›Full record

ArticleVaccines2022

Attitudes toward COVID-19 Vaccination: A Survey of Chinese Patients with Rheumatic Diseases.

Zixi Yi, Zhongqiang Yao, Dan Xu, Chuanhui Xu, Wenqiang Fang, Zhanfei Guo, Yong Wang, Jianlin Huang, Qin Li, Hong Zhang and 14 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Interventions to Improve COVID-19 Vaccine Hesitancy.Rheumatic diseases clinics of North America · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 2 countries.

Zixi YiDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0003-3812-7886
Zhongqiang YaoDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.
Dan XuDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.
Chuanhui XuDepartment of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore 999002, Singapore.
Wenqiang FangDepartment of Rheumatology and Immunology, Xinxiang Central Hospital, Xinxiang 453000, China.
Zhanfei GuoDepartment of Rheumatology and Immunology, Xinxiang Central Hospital, Xinxiang 453000, China.
Yong WangDepartment of Rheumatology and Immunology, The Southwest Hospital of Army Medical University, Chongqing 404100, China.
Jianlin HuangDepartment of Rheumatology and Immunology, Sun Yat-sen University Sixth Affiliated Hospital, Guangzhou 510275, China.
Qin LiDepartment of Rheumatology and Immunology, The First People's Hospital of Yunnan Province, Kunming 650300, China.
Hong ZhangDepartment of Rheumatology and Immunology, The First People's Hospital of Yunnan Province, Kunming 650300, China.
Anbin HuangDepartment of Rheumatology and Immunology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Lijun WuDepartment of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Zhenbiao WuDepartment of Rheumatology and Immunology, Air Force Medical University, Xi'an 710000, China.
Huifang GuoDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Fengxiao ZhangDepartment of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang 050000, China.
Jing LuDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang 110000, China.
Zhenchun ZhangDepartment of Rheumatology and Immunology, Linyi People's Hospital, Linyi 273300, China.
Zhongming YuDepartment of Rheumatology and Immunology, Shaoxing People's Hospital, Shaoxing 310009, China.
Zhanyun DaDepartment of Rheumatology and Immunology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Li LuoDepartment of Rheumatology and Immunology, Xinjiang Medical University Affiliated First Hospital, Urumqi 830001, China.
Bin WuDepartment of Rheumatology and Immunology, First People's Hospital of Jingzhou, Jingzhou 434000, China.
Henglian WuDepartment of Rheumatology and Immunology, Dongguan Tungwah Hospital, Dongguan 523000, China.
Lin ZengResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China.
Rong MuDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-9111-2643
Peking University · CNFirst People's Hospital of Yunnan Province · CNXinxiang Central Hospital · CNAir Force Medical University · CNArmy Medical University · CNFirst Hospital of China Medical University · CNFirst People's Hospital of Jingzhou · CNHebei General Hospital · CNHebei Medical University · CNLinyi People's Hospital · CNNantong University · CNPeople's Hospital of Xinjiang Uygur Autonomous Region · CNShaoxing People's Hospital · CNSun Yat-sen University · CNTan Tock Seng Hospital · SGTung Wah Hospital · CNWuhan Union Hospital · CNXinjiang Medical University · CN

Funding

Peking University Third Hospital No. BYSYDL2021005
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has imposed enormous morbidity and mortality burdens. Patients with rheumatic diseases (RDs) are vulnerable to the COVID-19 infection, given their immunocompromised status. Ensuring acceptance of the COVID-19 vaccine is important and has attracted attention by health professionals. In this study, we designed an online cross-sectional survey that used an online questionnaire from 8 May 2021 to 4 October 2021. Attitudes toward the COVID-19 vaccination, personal information, current disease activity status, adverse events (AEs), and knowledge sources of vaccines were collected. Descriptive statistics, nonparametric tests, and ordinal logistic regression were used to analyze the data. A total of 1022 questionnaires were received, among which 70.2% (720/1022) of patients with RDs agreed to vaccination, while only 31.6% of patients were actually vaccinated. Male, employed, high-income patients and those with inactive disease showed a more positive attitude. Concerns of AEs and disease flare were the main factors affecting vaccination willingness. Only 29.6% (304/1022) of patients thought they had received enough information about the COVID-19 vaccine from their doctors. In conclusion, most patients with RDs in China intended to get vaccinated, although the vaccination rate in this particular population was low. Rheumatologists should take more responsibility in COVID-19 vaccination education of patients with RDs.

Indexed as

attitudesCOVID-19rheumatic diseasesvaccine

Identifiers

PMID36298469
PMCPMC9611697
OpenAlexW4298003458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.